Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Price Target at $25.60

Astria Therapeutics, Inc. (NASDAQ:ATXS) has received a consensus rating of “Buy” from the six research firms that are currently covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $25.60.

ATXS has been the topic of a number of recent research reports. Oppenheimer upped their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Wedbush reissued an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Thursday, November 14th.

Astria Therapeutics Stock Performance

Shares of ATXS stock opened at $10.39 on Friday. Astria Therapeutics has a fifty-two week low of $4.50 and a fifty-two week high of $16.90. The company has a 50 day moving average price of $11.10 and a 200 day moving average price of $10.62. The stock has a market capitalization of $586.35 million, a P/E ratio of -4.97 and a beta of 0.71.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Astria Therapeutics by 23.4% in the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after acquiring an additional 480,184 shares during the period. American International Group Inc. raised its position in Astria Therapeutics by 49.4% in the 1st quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company’s stock valued at $346,000 after purchasing an additional 8,122 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in Astria Therapeutics in the 1st quarter valued at $200,000. Tidal Investments LLC acquired a new stake in Astria Therapeutics during the 1st quarter worth $1,664,000. Finally, Artal Group S.A. purchased a new position in Astria Therapeutics during the 1st quarter worth $12,445,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.